Valuation: DMS

Market Cap 31.23M 35.73M 28.82M 26.56M 50.06M 3.44B 51.17M 344M 135M 1.69B 134M 131M 5.8B P/E 2026 *
40.2x
P/E 2027 * 12.1x
Enterprise Value 46.63M 53.36M 43.03M 39.66M 74.75M 5.14B 76.41M 514M 202M 2.52B 200M 196M 8.66B EV / Sales 2026 *
0.82x
EV / Sales 2027 * 0.6x
Free-Float
69.9%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 17/07/2022
Director of Finance/CFO - 31/12/2021
Chief Tech/Sci/R&D Officer - 31/12/2018
Director TitleAgeSince
Chairman 53 17/07/2022
Director/Board Member 52 15/06/2025
Director/Board Member - 23/07/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 35.73M
-1.21%+1.26%-12.85%-18.91% 13.35B
-6.37%-15.89%+41.25%-12.42% 3.86B
-0.76%-0.17%+68.89%+112.37% 1.24B
-4.45%-0.26%-34.68%-61.49% 1.18B
-4.35%-2.94%-39.92%-47.56% 1.09B
-3.75%+6.82%-43.21% - 940M
-8.55%-20.41%+77.15%+90.57% 490M
+5.01%+12.02%+42.77% - 335M
+1.55%+1.73%-58.55%+239.01% 265M
Average -2.29%-0.12%+4.54%+43.08% 2.53B
Weighted average by Cap. -2.52%-0.29%-0.68%-8.29%

Financials

2026 *2027 *
Net sales 56.8M 65M 52.41M 48.31M 91.06M 6.26B 93.08M 626M 246M 3.07B 244M 239M 10.55B 65.9M 75.41M 60.81M 56.05M 106M 7.26B 108M 727M 286M 3.56B 283M 277M 12.24B
Net income 800K 915K 738K 680K 1.28M 88.16M 1.31M 8.82M 3.47M 43.18M 3.44M 3.36M 149M 2.6M 2.98M 2.4M 2.21M 4.17M 287M 4.26M 28.68M 11.28M 140M 11.17M 10.93M 483M
Net Debt 15.4M 17.62M 14.21M 13.1M 24.69M 1.7B 25.24M 170M 66.81M 831M 66.18M 64.73M 2.86B 8M 9.15M 7.38M 6.8M 12.83M 882M 13.11M 88.24M 34.71M 432M 34.38M 33.62M 1.49B
Logo DMS
Diagnostic Medical Systems (DMS) is France's leader in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: - radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; - development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine. Products and services are marketed primarily by exclusive retailers. Net sales (not including sold divisions) are distributed geographically as follows: Europe (49.6%), North and South America (17%), Asia (7.5%), Middle East (7.5%), Africa (3.1%), Oceania (1%) and other (14.3%).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-